Our cutting-edge proprietary technology is the driving force behind our strong research and vaccine development pipeline, helping the global health community better prepare for and combat life-threatening infectious disease outbreaks.
Our innovative vaccine technology platform – AdVac® – offers real hope for the accelerated development of vaccines and is designed to help the global health community better prepare for and combat life-threatening infectious disease outbreaks.
This technology was used in the development of our Ebola vaccine regimen, which was approved by the European Commission in July 2020 and has been deployed in the Democratic Republic of the Congo (DRC) and Rwanda. The AdVac® technology was also used to construct our HIV, RSV and Zika vaccine candidates.
Our SARS-CoV-2 vaccine research program is leveraging Janssen’s AdVac® technology in an effort to help combat the current COVID-19 pandemic.
Adenoviruses are a group of viruses that cause the common cold - so they're good for transporting things into humans.
Janssen’s AdVac® vectors are based on a specific type of adenovirus, which has been genetically modified so that it can no longer replicate in humans and cause disease.
|The AdVac® technology works by using an adenovirus as a vector (a carrier) of an antigen’s genetic code, to mimic components of a pathogen (a bacterium, virus, or other disease-causing organism). Antigens (components of a pathogen) are produced to mimic the pathogen, without causing severe disease.|
|When the body encounters the antigen the body will induce both a long-lasting humoral and cellular immune response against the antigen, by producing immune cells and antibodies.|
|In the future, if the body encounters the actual pathogen, the body will be able to respond faster and more effectively, as immune cells and antibodies specific to the pathogen will be rapidly produced in the body to prevent the pathogen from inducing disease.|
On March 30, 2020, Johnson & Johnson announced a lead vaccine candidate for COVID-19, Ad26.COV2.S. Our SARS-CoV-2 vaccine research program is leveraging Janssen’s AdVac® technology that provides the ability to rapidly develop new vaccine candidates.
During the Ebola epidemic in West Africa, Janssen responded by accelerating its Ebola vaccine development effort and scale up, resulting in the manufacturing of two million vaccine regimens in less than one year. This two-dose regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), is now approved by the European Commission.